

Supported by  *P&G Health*

Early Intervention in Acute Upper Respiratory Tract Infections

An experts consensus for patient management

Authors

John BELL
Antonio CHUA
Ronald ECCLES
Sundeep SALVI
Natalie SCHELLACK
De Yun WANG



FOREWORD

Upper respiratory tract infections (URTIs) are one of the most common diagnoses in the primary care setting across the world¹, with more than 18.8 billion cases² occurring worldwide every year. Most adults will have 2-4 episodes of acute URTI each year, while children have an average of 6-10 episodes^{3,4,5,6}.

Most URTIs are of short duration and with mild symptoms, but some can lead to serious complications such as pneumonia, rhinosinusitis, otitis media, and exacerbation of asthma and COPD among high-risk individuals. It not only affects an individual's health, but also his/her social life, sleep, school, and/or work performance, representing an important burden to society. However, for most URTIs neither cure nor wide-scale prevention through immunization is yet available – so appropriate treatment requires early intervention. During the pandemic of an acute URTI, early intervention is even more important to prevent viral transmission and infection in susceptible or at-risk populations.

The consensus collated in this paper is an important step to help everyone better understand the impact of URTI and the definition, benefits, and impact of early intervention. This would go a long way towards its advocacy among healthcare professionals as well as the public.



Mr John BELL
Practitioner pharmacist/ Teacher, University of Technology Sydney, Australia (Community management for acute URTI)



Dr Antonio CHUA
ENT consultant, Philippines (Adult and Paediatric care for acute URTI)



Prof Ronald ECCLES
Emeritus Professor, Cardiff University, UK (Expertise in common cold and cough treatments)



Dr Sundeep SALVI
Director, Pulmocare Research and Education (PURE) Foundation, India (Respiratory and pulmonary diseases)



Prof Natalie SCHELLACK
Registered pharmacist, Professor and Head of Pharmacology, University of Pretoria, Republic of South Africa (Clinical pharmacy for acute URTI)





Prof De Yun WANG
Research Professor, National University of Singapore, Singapore (Rhinology, viral infection of the upper airway, mucoadhesive gel spray innovation)

WHAT IS EARLY INTERVENTION?

Before defining early intervention, it is critical to understand the life cycle of an acute URTI.

URTIs are mostly caused by viruses and there are over 200 types of respiratory viruses that cause URTIs^{1,3}. The development of viral URTIs is largely similar and constitutes four stages. However, there are some variations in duration and symptom manifestation at each stage across different types of URTI viruses.

How does an acute URTI develop?^{1,7}



STAGE 1
The viruses enter via nasal/nasopharyngeal epithelium^{8,9,10} and bind to receptor of epithelial cells

STAGE 2
The viruses uncoat, replicate, and release to invade more cells

STAGE 3
The viruses multiply to a certain extent and trigger immune responses from an individual

STAGE 4
The viruses replicate to a maximum load and the individual experiences more severe symptoms

Early symptoms of acute URTI include sniffing, sneezing, and throat irritation, with occasional chills, headache, and malaise. They can appear anytime within the first 36-48 hours of infection.

Late symptoms include nasal discharge/ obstruction, throat pain from inflamed tonsils/ adenoids and cough. Chills, headache and malaise may also occur. These tend to develop over several days and last 1 week or more.

WHAT IS EARLY INTERVENTION?

When to intervene?

In absence of symptoms

BEFORE
STAGE 1

Those frequently exposed to infected individuals should intervene even in the absence of symptoms when they feel they are at risk of catching an URTI. Intervention at this stage can create a hostile environment for viruses to bind and replicate.

As early as possible

STAGE 1

STAGE 2

STAGE 3

It is best to intervene as early as possible upon 1st symptom appearance to reduce the chance of developing a full blown acute URTI. It is easier to slow down or even halt viral replication at the early stages of infection.

- Within 36 hours of 1st symptom appearance
- Common early symptoms include sniffing, sneezing and throat irritation, with occasional chills, headache and malaises.

After symptoms progress

STAGE 4

Intervention may not be as effective in preventing the development of a full blown URTI or the progression of symptoms once they become disturbing, as viruses have already replicated to a large amount. However, intervening at this stage can still slow down viral replication and minimise spreading to other people.

- ~48 hours to one week of 1st symptom appearance
- Late symptoms include nasal discharge/obstruction, throat pain from inflamed tonsils/ adenoids, and cough. Chills, headache and malaise may also occur at this stage.

“The earlier the better when it comes to early intervention of any infection... it is like putting a fire out.”

– R. Eccles

“Where there is exposure to the virus; the exposed person may start [using early intervention] as a preventive measure.”

– A. Chua

“Once the viruses replicated in huge numbers and go down to the throat, it will be a bit late...However, we should intervene at any time to stop viral replication.”

– D.Y Wang

BENEFITS OF EARLY INTERVENTION

As there is no cure nor prevention for acute URTIs, it is important to intervene as early as possible to disrupt the viral replication cycle. There are several benefits of timely and appropriate early intervention in acute URTI.

Reduce chances of developing a full blown acute URTI

Early intervention can slow down and potentially halt viral replication. This may potentially allow the immune system to catch up and eliminate the viruses.

Decrease severity of acute URTI symptoms

Even if a full blown acute URTI is unavoidable, early intervention can result in shorter or less severe symptoms as it reduces viral load in the infected person.

Reduce viral transmission

Early intervention can reduce breadth of viral transmission by preventing virus particles from reaching their host cells and creating a hostile environment for replication.

HIGH RISK GROUPS FOR ACUTE URTI

URTI is a multi-symptom illness, with symptom profiles varying across individuals in terms of severity, duration, and types ^{11,12}. However, some people are at higher risk of having an URTI, spreading URTI viruses, or developing more serious URTI complications ¹³.



Pre-existing respiratory conditions or smokers

- 80-85% of asthma exacerbations among school age children are associated with URTI ^{11,12}.
- URTI is associated with over 50% of COPD exacerbations ¹⁴. The presence of URTI leads to more severe exacerbations, longer recovery times, and can lead to hospitalisation ¹⁴.
- Smoking is a known risk factor for URTI, both for the people who smoke and those around them.

“Patients with asthma or COPD are at high risk...you will need to intervene as fast as possible to avoid complications.”
– N. Schellack



Children

Children can have 2-4 more URTI episodes than adults per year ¹. While URTI symptoms only persist in 20% of adults at day 10, 73% of children still experience symptoms ¹⁵.

“Children often come home from school or day care with all types of infections and spread them around to the rest of the family.” – J. Bell



Elderly

Upper and lower respiratory tract infections are the leading causes of death and disability due to infection in the elderly. Compared to the general population, hospitalisation rate for URTI-related pneumonia is 12 times higher for those aged over 75 years ¹⁶.



Immunocompromised individuals

Those with cystic fibrosis, HIV, use of corticosteroids, transplantation, and post-splenectomy are at high risk of developing severe URTI complications such as pneumonia ¹³.



Those with frequent contact with infected individuals or high-risk groups

As URTI can easily spread from an infected individual to people around them by contact and airborne transmission ¹⁷, family members of an infected person, healthcare professionals, and adults having frequent contact with infected children can also be at high risk of developing acute URTI.

“As an example - in a household of five, if everyone uses early intervention when one family member caught URTI, four cases can be prevented.” - S. Salvi

WHICH EARLY INTERVENTION?

Most URTI guideline recommendations focus on treatments that alleviate symptoms such as pain, fever, or inflammation. However, four characteristics¹⁸ of an ideal early intervention include:

- ✓ Quick onset of action to tackle rapid viral replication
- ✓ Safe to use across general population
- ✓ Effective against a wide variety of pathogens
- ✓ Low risk of resistance development against the intervention

Experts also recommend several early interventions such as mucoadhesive gel nasal sprays and neuraminidase inhibitors. Mucoadhesive gel nasal sprays in particular have been gaining more attention from experts in recent years.


What is mucoadhesive gel intranasal spray?

Mucoadhesive gel intranasal spray is a medical device that contains ingredients such as Carbopol, Carrageenan and Hydroxypropyl Methylcellulose (HPMC), and have known physical actions against virus particles in the nose.

The intranasal spray should be used at the first symptom of an emerging acute URTI or upon exposure to URTI viruses.


Mechanism of action ✓ Quick onset of action

The intranasal spray acts at the back of the nose directly where acute URTI viruses start to bind and replicate. Mucoadhesive gel intranasal sprays can work in the following ways:




1. Trap

Trap the inhaled URTI viruses and cover receptor surface, preventing viruses from reaching their complementary receptors



2. Slow Down

In a formulation with lower pH of 3.5-4.0, it can create a hostile environment for URTI viruses and slow down viral replication



3. Washout

Have a nasal washout effect to flush out viruses either through nose blowing or swallowing

Scientific evidence ✓ Safe ✓ Effective ✓ Low risk of resistance


Several human clinical studies^{19, 20, 21} indicate that the mucoadhesive gel intranasal spray is effective in reducing URTI duration and symptom severity, and is safe to use.

MUCOADHESIVE GEL INTRANASAL SPRAY:

REDUCES COLD DURATION*
FOR UP TO

2.1²⁰ to 2.4¹⁹ days


*Based on comparison of respective calculations of symptoms duration versus controlled groups in the respective studies



REDUCES COLD SEVERITY*
FOR UP TO

10²¹ to 17¹⁹ %


*Based on comparison of respective calculations of Total Symptoms Score versus controlled groups in the respective studies



FORWARD LOOKING ACTION







As the most frequently observed infectious disease, acute URTI warrants more attention and proactive management to reduce its burden. We suggest that every individual presenting to a pharmacy/clinic with suspected URTI symptoms, or has comorbid conditions such as a history of asthma/COPD, or has frequent contact with infected individuals should receive a “value brief” on the benefits of early intervention for acute URTI to help pre-empt current and future URTIs.

EFFECTIVE EARLY INTERVENTION:



When it comes to selecting an appropriate early intervention for acute URTI, mucoadhesive gel intranasal spray fits the requirements as it is effective and well tolerated with a rapid onset of action. Consumer education should focus on when, why and how to use the intranasal spray to effectively fight against acute URTI.

Early Intervention Guide

WHEN	WHY	HOW
 As early as possible upon symptom appearance	 Reduce the chance of developing a full blown acute URTI	<ul style="list-style-type: none">• Apply intervention directly into each nostril• Use in combination with symptomatic treatments• Administer for at least 2-4 days, and beyond should there be progression of symptoms• Continue to use until symptoms subside
 When symptoms are prominent	 Decrease duration or severity of symptoms, and minimise viral transmission	
 In absence of symptoms when being exposed to an infected individual	 Prevent virus particles from binding and reduce the chance of developing an URTI	



REFERENCES

- 1 Eccles R. Understanding the symptoms of the common cold and influenza. *Lancet Infect Dis.* 2005;5(11):718-725. doi:10.1016/S1473-3099(05)70270-X
- 2 Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. *Arch Intern Med.* 2003;163(4):487-494. doi:10.1001/archinte.163.4.487
- 3 Heikkinen T, Järvinen A. The common cold. In: *Lancet*. Vol 361. Elsevier Limited; 2003:51-59. doi:10.1016/S0140-6736(03)12162-9
- 4 Spector SL. The common cold: Current therapy and natural history. *J Allergy Clin Immunol.* 1995;95(5 SUPPL.):1133-1138. doi:10.1016/S0091-6749(95)70218-0
- 5 *Viral and Other Infections of the Human Respiratory Tract.* Springer Netherlands; 1996. doi:10.1007/978-94-011-7930-0
- 6 Winther B, Gwaltney JM, Mygind N, Hendley JO. Viral-induced rhinitis. In: *American Journal of Rhinology*. Vol 12. OceanSide Publications Inc.; 1998:17-20. doi:10.2500/105065898782102954
- 7 Jackson GG, Dowling HF. Transmission of the common cold to volunteers under controlled conditions. IV. Specific immunity to the common cold. *J Clin Invest.* 1959;38(5):762-769. doi:10.1172/JCI103857
- 8 Medina RA, García-Sastre A. Influenza A viruses: New research developments. *Nat Rev Microbiol.* 2011;9(8):590-603. doi:10.1038/nrmicro2613
- 9 Vareille M, Kieninger E, Edwards MR, Regamey N. The airway epithelium: Soldier in the fight against respiratory viruses. *Clin Microbiol Rev.* 2011;24(1):210-229. doi:10.1128/CMR.00014-10
- 10 Tan K Sen, Lim RL, Liu J, et al. Respiratory Viral Infections in Exacerbation of Chronic Airway Inflammatory Diseases: Novel Mechanisms and Insights From the Upper Airway Epithelium. *Front Cell Dev Biol.* 2020;8. doi:10.3389/fcell.2020.00099
- 11 Guilbert TW, Denlinger LC. Role of infection in the development and exacerbation of asthma. *Expert Rev Respir Med.* 2010;4(1):71-83. doi:10.1586/ers.09.60
- 12 Rakes GP, Arruda E, Ingram JM, et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care: IgE and eosinophil analyses. *Am J Respir Crit Care Med.* 1999;159(3):785-790. doi:10.1164/ajrccm.159.3.9801052
- 13 Heikkinen T, Ruuskanen O. Upper Respiratory Tract Infection. In: *Encyclopedia of Respiratory Medicine, Four-Volume Set.* Elsevier Inc.; 2006:385-388. doi:10.1016/B0-12-370879-6/00416-6
- 14 Wedzicha JA. Role of viruses in exacerbations of chronic obstructive pulmonary disease. *Proc Am Thorac Soc.* 2004;1(2):115-120. doi:10.1513/pats.2306030
- 15 Cotton MF, Innes S, Jaspan H, Madide A, Rabie H. Management of upper respiratory tract infections in children. *South African Fam Pract.* 2008;50(2):6-12. doi:10.1080/20786204.2008.10873685
- 16 Meyer KC. Lung infections and aging. *Ageing Res Rev.* 2004;3(1):55-67. doi:10.1016/j.arr.2003.07.002
- 17 Kutter JS, Spronken MI, Fraaij PL, Fouchier RA, Herfst S. Transmission routes of respiratory viruses among humans. *Curr Opin Virol.* 2018;28:142-151. doi:10.1016/j.coviro.2018.01.001
- 18 Rollinger JM, Schmidtke M. The human rhinovirus: Human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. *Med Res Rev.* 2011;31(1):42-92. doi:10.1002/med.20176
- 19 Hull D, Rennie P, Noronha A, et al. Effects of creating a non-specific, virus-hostile environment in the nasopharynx on symptoms and duration of common cold. *Acta Otorhinolaryngol Ital.* 2007;27(2):73-77.
- 20 Ludwig M, Enzenhofer E, Schneider S, et al. Efficacy of a Carrageenan nasal spray in patients with common cold: A randomised controlled trial. *Respir Res.* 2013;14(1):124. doi:10.1186/1465-9921-14-124
- 21 Eccles R, Winther B, Johnston SL, Robinson P, Trampisch M, Koelsch S. Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: The ICICC trial. *Respir Res.* 2015;16(1). doi:10.1186/s12931-015-0281-8

This paper is intended for Healthcare Professional educational purposes only. The information provided reflects only the perspectives and opinions of the authors following an expert round-table discussion. The development of this paper was supported by P&G Health and Ipsos.